Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Ultrasound needle guide trial pulled before it even started

NCT ID NCT03879161

Knowledge-focused Sponsor: Johns Hopkins University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled This study
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study was designed to test a new ultrasound device with a needle guide for placing a needle into the femoral artery during liver cancer treatment. The goal was to see if the device made the procedure safer and more accurate. However, the trial was withdrawn before enrolling any participants, so no results are available.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Vu-Path™ percutaneous ultrasound device with needle guide

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Expected to start

Sep 2026

An estimate. Start dates often move.

Expected to finish

Dec 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Male or female participants, 18 years of age or older at the time of enrollment. * Participants meeting all medical conditions for percutaneous angiography. * International Normalized Ratio (INR) \<1.3. * Written informed consent to participate in the study. * Ability to comply with the requirements of the study procedures. Exclusion Criteria: * Fibrous tissue in access path. * Active skin infection at the point of needle insertion. * Hemophilia, thrombocytopenia, coagulopathy, or other elevated risk for bleeding or abnormal clotting * Use of antithrombotic medication. * For participants taking warfarin or other anticoagulant medication, INR \>1.3. * Participants who cannot tolerate mild sedation. * Participants with the following laboratory values, unless approved by hematologist: Platelet count \<100,000/mL, Activated Partial Thromboplastin Time (APTT) \>39 sec or Prothrombin Time (PT) \>15 sec * Pregnancy or lactation * Patient is unable to comply with requirements of the procedure, i.e. holding breath * Participation in an investigational trial within 30 days of enrollment. * Any form of substance abuse (including drug or alcohol abuse), psychiatric disorder, or any chronic condition that could, in the opinion of the investigator, of interfering with the conduct of the study. * Participants who are uncooperative or cannot follow instructions.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Metastatic liver cancer are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

liver cancer Liver Neoplasms metastatic neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Vascular access

Contacts and locations

Locations

  • Johns Hopkins School of Medicine

    Baltimore, Maryland, 21287, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.